Abstract: Use of a siRNA molecule selected from the group consisting of SEQ ID NO: 173 to 344 for treating a disease associated with a pathological cell population in a subject in need thereof is disclosed. Pharmaceutical compositions and articles of manufacture comprising the siRNAs are also disclosed.

Abstract: A method of treating cancer in a subject in need thereof is disclosed. The method comprises administering to the subject a siRNA molecule capable of inducing degradation of an mRNA encoding a polypeptide of SEQ ID NO: 1 in cells of the cancer thereby treating the cancer in the subject.

Abstract: The invention provides a method of treating cancer by administering to a subject in need thereof, the subject being treated with an anti-cancer antibody therapy, a therapeutically effective amount of a delocalized lipophilic cation (DLC) compound such as MKT-077 which is capable of binding mortalin as an adjuvant for the anti-cancer antibody therapy. Also provided are pharmaceutical compositions and article of manufacturer for treating cancer which comprise the DLC compound as an adjuvant for anti-cancer antibody therapy.

Abstract: Use of a siRNA molecule selected from the group consisting of SEQ ID NO: 173 to 344 for treating a disease associated with a pathological cell population in a subject in need thereof is disclosed. Pharmaceutical compositions and articles of manufacture comprising the siRNAs are also disclosed.

Abstract: A method of treating a disease associated with a pathological cell population is disclosed. The method comprises increasing an association of complement with the pathological cell population in a subject in need of treatment, and decreasing a level and/or activity of a polypeptide in the pathological cell population, the polypeptide being at least 70 percent similar to SEQ ID NO: 1. A method of treating a disease associated with a pathological cell population is further disclosed. The method comprises administering to a subject in need of treatment a substantially cell membrane-impermeable compound for decreasing a level and/or activity of a polypeptide in the pathological cell population, the polypeptide being at least 70 percent similar to SEQ ID NO: 1; and, optionally, increasing an association of complement with the pathological cell population. A method of treating a disease associated with pathological complement-mediated cytotoxicity is yet further disclosed.